Aktiespot

Daewon Pharmaceutical Co., Ltd. (Daewonpharm) Aktie

003220.KS

Geschlossen
₩12,310.00+1,070.00 (+9.52%)
Chart wird geladen...

Daewonpharm

Eröffnung13,670.00
Hoch13,670.00
Tief11,610.00
Volumen3.54M
P/EN/A
Marktkapitalisierung263.85B
52-Wochen-Hoch14,700.00
52-Wochen-Tief8,070.00
Durchschn. Volumen34.41k
Dividende2.22%
Beta0.16
EPSN/A

Über Daewon Pharmaceutical Co., Ltd. (Daewonpharm) Aktie

Daewon Pharmaceutical Co., Ltd., a pharmaceutical company, manufactures and sells medicines and medical supplies in South Korea. It offers various medicines for circulatory, respiratory, antibiotic, chemotherapy, and psychoneurosis use. The company's principal products include Oramin-F Soft Cap, a multivitamin product; Pelubi Tablet, a NSAID product for pain relief; Freefol-MCT Inj., a microemulsion propofol for the anti-exogenous infectious bacteria; Megex-I Susp, a medicine that supplements subalimentation of cancer patients; Trigel Susp, a therapy for gastritis and duodenal ulcer; and Renamezin Cap, a spherical carbonaceous adsorbent for chronic kidney disease. It also exports its products to approximately 40 countries primarily in Asia, Central and South America, the Middle East, CIS, and Africa. The company was founded in 1958 and is headquartered in Seoul, South Korea.

Unternehmensinformationen

Börse: KSE (KSC)
Sektor: Sundhed
Branche: Lægemiddelproducenter – Special og generisk
Adresse:
386 Cheonhodae-ro
Seoul, South Korea
Telefon: + 82 2 2204 7000

Analystenempfehlungen

Diese Übersicht gibt einen schnellen Einblick, wie Analysten das Aktienpotenzial basierend auf ihren neuesten Analysen und Kurszielen bewerten.

Niedrigstes Kursziel
13,000.00
5.6%
Durchschnittliches Kursziel
14,666.67
19.1%
Median Kursziel
15,000.00
21.9%
Höchstes Kursziel
16,000.00
30.0%

Andere sehen auch: